Rufloxacin Once Daily Versus Ciprofloxacin Twice Daily in the Treatment of Patients with Acute Uncomplicated Pyelonephritis

D. Bach, Annelise van den Berg-Segers, Andreas Hubner, Gerard van Breukelen, Marina Cesana, Yannick Pletan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: We compare the bacteriological and clinical efficacy of rufloxacin and ciprofloxacin in patients with acute uncomplicated pyelonephritis. Materials and Methods: A total of 110 outpatients was enrolled in a randomized, double-blind multicenter study and treated for 10 days with 200 mg. rufloxacin daily (after a loading dose of 400 mg. on day 1) or 500 mg. ciprofloxacin twice daily. Bacteriological and clinical efficacy was based on the accumulated outcomes assessed at the end of treatment, and at 2 and 4 to 6 weeks. Results: The bacteriological and clinical success rates of rufloxacin and ciprofloxacin were comparable: 55.6 percent versus 58.8 percent and 74 percent versus 71 percent, respectively (95 percent confidence interval -28 percent to +22 percent and -20 percent to +25 percent, respectively). Both study medications were well tolerated. Conclusions: Rufloxacin once daily is a good alternative in the outpatient treatment of acute uncomplicated pyelonephritis.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalJournal of Urology
Volume154
Issue number1
DOIs
Publication statusPublished - 1995

Fingerprint

Pyelonephritis
Ciprofloxacin
Outpatients
Therapeutics
Double-Blind Method
Multicenter Studies
Confidence Intervals
rufloxacin

ASJC Scopus subject areas

  • Urology

Cite this

Rufloxacin Once Daily Versus Ciprofloxacin Twice Daily in the Treatment of Patients with Acute Uncomplicated Pyelonephritis. / Bach, D.; van den Berg-Segers, Annelise; Hubner, Andreas; van Breukelen, Gerard; Cesana, Marina; Pletan, Yannick.

In: Journal of Urology, Vol. 154, No. 1, 1995, p. 19-24.

Research output: Contribution to journalArticle

Bach, D. ; van den Berg-Segers, Annelise ; Hubner, Andreas ; van Breukelen, Gerard ; Cesana, Marina ; Pletan, Yannick. / Rufloxacin Once Daily Versus Ciprofloxacin Twice Daily in the Treatment of Patients with Acute Uncomplicated Pyelonephritis. In: Journal of Urology. 1995 ; Vol. 154, No. 1. pp. 19-24.
@article{5f16ab121a46430f88c4bd179375b301,
title = "Rufloxacin Once Daily Versus Ciprofloxacin Twice Daily in the Treatment of Patients with Acute Uncomplicated Pyelonephritis",
abstract = "Purpose: We compare the bacteriological and clinical efficacy of rufloxacin and ciprofloxacin in patients with acute uncomplicated pyelonephritis. Materials and Methods: A total of 110 outpatients was enrolled in a randomized, double-blind multicenter study and treated for 10 days with 200 mg. rufloxacin daily (after a loading dose of 400 mg. on day 1) or 500 mg. ciprofloxacin twice daily. Bacteriological and clinical efficacy was based on the accumulated outcomes assessed at the end of treatment, and at 2 and 4 to 6 weeks. Results: The bacteriological and clinical success rates of rufloxacin and ciprofloxacin were comparable: 55.6 percent versus 58.8 percent and 74 percent versus 71 percent, respectively (95 percent confidence interval -28 percent to +22 percent and -20 percent to +25 percent, respectively). Both study medications were well tolerated. Conclusions: Rufloxacin once daily is a good alternative in the outpatient treatment of acute uncomplicated pyelonephritis.",
author = "D. Bach and {van den Berg-Segers}, Annelise and Andreas Hubner and {van Breukelen}, Gerard and Marina Cesana and Yannick Pletan",
year = "1995",
doi = "10.1016/S0022-5347(01)67213-6",
language = "English",
volume = "154",
pages = "19--24",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Rufloxacin Once Daily Versus Ciprofloxacin Twice Daily in the Treatment of Patients with Acute Uncomplicated Pyelonephritis

AU - Bach, D.

AU - van den Berg-Segers, Annelise

AU - Hubner, Andreas

AU - van Breukelen, Gerard

AU - Cesana, Marina

AU - Pletan, Yannick

PY - 1995

Y1 - 1995

N2 - Purpose: We compare the bacteriological and clinical efficacy of rufloxacin and ciprofloxacin in patients with acute uncomplicated pyelonephritis. Materials and Methods: A total of 110 outpatients was enrolled in a randomized, double-blind multicenter study and treated for 10 days with 200 mg. rufloxacin daily (after a loading dose of 400 mg. on day 1) or 500 mg. ciprofloxacin twice daily. Bacteriological and clinical efficacy was based on the accumulated outcomes assessed at the end of treatment, and at 2 and 4 to 6 weeks. Results: The bacteriological and clinical success rates of rufloxacin and ciprofloxacin were comparable: 55.6 percent versus 58.8 percent and 74 percent versus 71 percent, respectively (95 percent confidence interval -28 percent to +22 percent and -20 percent to +25 percent, respectively). Both study medications were well tolerated. Conclusions: Rufloxacin once daily is a good alternative in the outpatient treatment of acute uncomplicated pyelonephritis.

AB - Purpose: We compare the bacteriological and clinical efficacy of rufloxacin and ciprofloxacin in patients with acute uncomplicated pyelonephritis. Materials and Methods: A total of 110 outpatients was enrolled in a randomized, double-blind multicenter study and treated for 10 days with 200 mg. rufloxacin daily (after a loading dose of 400 mg. on day 1) or 500 mg. ciprofloxacin twice daily. Bacteriological and clinical efficacy was based on the accumulated outcomes assessed at the end of treatment, and at 2 and 4 to 6 weeks. Results: The bacteriological and clinical success rates of rufloxacin and ciprofloxacin were comparable: 55.6 percent versus 58.8 percent and 74 percent versus 71 percent, respectively (95 percent confidence interval -28 percent to +22 percent and -20 percent to +25 percent, respectively). Both study medications were well tolerated. Conclusions: Rufloxacin once daily is a good alternative in the outpatient treatment of acute uncomplicated pyelonephritis.

UR - http://www.scopus.com/inward/record.url?scp=0029052116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029052116&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)67213-6

DO - 10.1016/S0022-5347(01)67213-6

M3 - Article

VL - 154

SP - 19

EP - 24

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -